A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants (NCT06576271)
A Phase 1, First-time-in-human, Four-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung disease associated with connective tissue disease (Part D)
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Scottsdale, Arizona
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- GSK Investigational Site — Scottsdale, Arizona
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Las Vegas, Nevada
- GSK Investigational Site — Columbus, Ohio
- GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — San Juan Bautista,
- GSK Investigational Site — San Miguel de Tucumán,
- GSK Investigational Site — Porto Alegre, Rio Grande do Sul
- GSK Investigational Site — Juiz de Fora,
- GSK Investigational Site — Porto Alegre,
- GSK Investigational Site — Salvador,
- GSK Investigational Site — Bydgoszcz,
- GSK Investigational Site — Krakow,
- GSK Investigational Site — Poznan,
- GSK Investigational Site — Warsaw,
- GSK Investigational Site — Wroclaw,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Bilbao,
- GSK Investigational Site — Pamplona,
- GSK Investigational Site — Sabadell Barcelona,
- GSK Investigational Site — Valladolid,
- GSK Investigational Site — Cambridge,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.